The Correlation Between SPP1 and Immune Escape of EGFR Mutant Lung Adenocarcinoma Was Explored by Bioinformatics Analysis

BACKGROUND: Immune checkpoint inhibitors have achieved breakthrough efficacy in treating lung adenocarcinoma (LUAD) with wild-type epidermal growth factor receptor (EGFR), leading to the revision of the treatment guidelines. However, most patients with EGFR mutation are resistant to immunotherapy. I...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Yi, Hao, Shiying, Xiang, Cheng, Han, Yaguang, Shang, Yanhong, Zhen, Qiang, Zhao, Yiyi, Zhang, Miao, Zhang, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222997/
https://www.ncbi.nlm.nih.gov/pubmed/34178613
http://dx.doi.org/10.3389/fonc.2021.592854

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222997/
https://www.ncbi.nlm.nih.gov/pubmed/34178613
http://dx.doi.org/10.3389/fonc.2021.592854

Ejemplares similares